Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Bavarian Nordic A/S buy Slaandjivaa

Start price
€32.77
18.09.17 / 50%
Target price
€37.00
25.09.17
Performance (%)
15.24%
End price
€37.77
25.09.17
Summary
This prediction ended on 25.09.17 with a price of €37.77. The BUY prediction by Slaandjivaa finished with a performance of 15.24%. Slaandjivaa has 50% into this prediction

Bavarian Nordic (symbol: BAVA) is a biotechnology company that specializes in developing innovative vaccines for serious diseases such as cancer and infectious diseases like Ebola and COVID-19. The company has a broad portfolio of vaccines that are under development and has collaboration agreements with various pharmaceutical companies and government agencies. Bavarian Nordic's flagship product is its cancer vaccine known as PROSTVAC, which is currently undergoing clinical trials for the treatment of prostate cancer. The company is listed on the NASDAQ Copenhagen stock exchange and has a market capitalization of approximately $925 million as of May 2021.

Performance without dividends (%)
Name 1w 1m 1y 3y
Bavarian Nordic A/S 2.977% 2.977% 23.077% -30.088%
iShares Core DAX® -3.935% -3.998% 11.192% 10.824%
iShares Nasdaq 100 -3.608% -9.386% 22.243% 34.145%
iShares Nikkei 225® -4.513% -8.017% 5.961% 2.360%
iShares S&P 500 -2.607% -4.265% 21.865% 36.823%

Comments by Slaandjivaa for this prediction

In the thread Bavarian Nordic A/S diskutieren
Prediction Buy
Perf. (%) 15.24%
Target price 37.000
Change
Ends at 25.09.17

Slaandjivaa stimmt der Buy-Einschätzung von sebbo zu

Slaandjivaa stimmt am 18.09.2017 der Buy-Einschätzung von sebbo mit dem Kursziel 37€ zu.
Überschrift: Bavarian Nordic

Prediction Buy
Perf. (%) 15.24%
Target price 37.000
Change
Ends at 25.09.17

(Zielkurs erreicht)